BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SSGJ-611 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SSGJ-611\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07767253-1275@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SSGJ-611: Phase 3 readout est. (NCT07767253)
DESCRIPTION:SSGJ-611\, phase 3\, Atopic Dermatitis.\nStudy: Evaluation of 6
 11 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)\nEsti
 mated primary completion: September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ssgj-611#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07767253
URL:https://assetmemo.bio/drug/ssgj-611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039669-1275@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SSGJ-611: Phase 3 readout est. (NCT07039669)
DESCRIPTION:SSGJ-611\, phase 3.\nStudy: Evaluation of 611 in Chinese Adults
  Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ssgj-611#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07039669
URL:https://assetmemo.bio/drug/ssgj-611#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
